tiprankstipranks
Trending News
More News >

Inozyme Pharma Approves Executive Bonuses Amid Merger

Story Highlights
Inozyme Pharma Approves Executive Bonuses Amid Merger

Don’t Miss TipRanks’ Half-Year Sale

Inozyme Pharma ( (INZY) ) has issued an update.

On May 16, 2025, Inozyme Pharma entered into a Merger Agreement with BioMarin Pharmaceutical and Incline Merger Sub. Subsequently, on May 30, 2025, the company’s Board of Directors approved transaction bonuses for key executives, contingent on the merger’s completion, to incentivize continued employment through the closing date.

The most recent analyst rating on (INZY) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Inozyme Pharma stock, see the INZY Stock Forecast page.

Spark’s Take on INZY Stock

According to Spark, TipRanks’ AI Analyst, INZY is a Underperform.

Inozyme Pharma’s stock score reflects its early-stage biotechnology status with significant operational losses, zero revenue, and ongoing cash burn. Technical indicators show short-term momentum but highlight potential overbought conditions. The negative P/E ratio underscores the lack of profitability, and with no earnings data or corporate events provided, the score is primarily driven by weak financial performance.

To see Spark’s full report on INZY stock, click here.

More about Inozyme Pharma

Inozyme Pharma, Inc. operates in the pharmaceutical industry, focusing on developing therapies for rare mineralization disorders.

Average Trading Volume: 2,021,184

Technical Sentiment Signal: Buy

Current Market Cap: $256.3M

For an in-depth examination of INZY stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1